Pakuła Dorota, Marek Bogdan, Kajdaniuk Dariusz, Kos-Kudła Beata, Borgiel-Marek Halina, Krysiak Robert, Gatnar Aleksander, Pakuła Piotr
II Oddział Chorób Wewnetrznych z Pododdziałem Endokrynologii i Diabetologii, Wojewódzki Szpital Specjalistyczny nr 3, Rybnik.
Endokrynol Pol. 2007 Jul-Aug;58(4):364-74.
Cardiac natriuretic peptide hormones, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), are synthesized and secreted by the heart, producing several biological effects, such as natriuresis, vasorelaxation and hypotension. During the last decade these peptides, especially BNP, have received increasing attention as potential markers of cardiovascular disease. Their measurements can be used to diagnose heart failure, including diastolic dysfunction, and using them has been shown to save money. BNP levels can enable the differentiation between dyspnoic patients secondary to ventricular dysfunction and subjects with primary respiratory disorders. Moreover, there is good evidence that natriuretic peptides may have a diagnostic role in arterial hypertension, acute coronary syndromes, pulmonary hypertension, some valvular heart disease and some disorders affecting other systems (diabetes or thyroid disorders). In this paper we discuss the clinical utility of assessment of natriuretic peptide hormones in the diagnosis of various clinical conditions and their use as pharmacological agents.
心脏利钠肽激素,即心房利钠肽(ANP)和B型利钠肽(BNP),由心脏合成并分泌,产生多种生物学效应,如利钠、血管舒张和低血压。在过去十年中,这些肽,尤其是BNP,作为心血管疾病的潜在标志物受到越来越多的关注。它们的检测可用于诊断心力衰竭,包括舒张功能障碍,并且已证明使用它们可节省费用。BNP水平能够区分继发于心室功能障碍的呼吸困难患者和原发性呼吸系统疾病患者。此外,有充分证据表明利钠肽可能在动脉高血压、急性冠状动脉综合征、肺动脉高压、某些瓣膜性心脏病以及一些影响其他系统的疾病(糖尿病或甲状腺疾病)中具有诊断作用。在本文中,我们讨论了评估利钠肽激素在各种临床病症诊断中的临床实用性及其作为药物制剂的用途。